Literature DB >> 15198127

Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis.

Isidro Ferrer1, Begoña Martín, José G Castaño, José J Lucas, Dolores Moreno, Montse Olivé.   

Abstract

Inclusion body myositis (IBM) and myofibrillar myopathy (MM) are diseases characterized by the abnormal accumulation of proteins in muscle fibers, including desmin, alphaB-crystallin, gelsolin, actin, kinases, and phospho-tau, along with ubiquitin in muscle fibers, suggesting abnormal protein degradation as a possible cause of the surplus myopathy. Since the ubiquitin-proteasome system plays a crucial role in non-lysosomal protein degradation, the present study has examined by immunohistochemistry the expression of components of the catalytic core of 20S proteasomes and its regulators: 19S and PA28alpha/beta, and the expression of immunoproteasome subunits LMP2, LMP7, and MECL1 in 8 patients with MM and 10 patients with IBM. The patients with MM were from 6 unrelated families, 2 sporadic cases, I with autosomal recessive and 5 with autosomal dominant inheritance. One sporadic patient had a de novo R406W mutation in the desmin gene, and 1 patient with autosomal dominant MM had a single amino acid deletion at position 366 in the desmin gene. Increased immunoreactivity to 20S, 19S, and PA28alpha/beta colocalizing abnormal protein deposits, as revealed in consecutive serial sections, was seen in all cases with MM and IBM. In all cases, the subunits of the immunoproteasome LMP2, LMP7, and MECL1 colocalized with proteasomal immunoreactivity and abnormal protein accumulation. Immunohistochemistry revealed focal MHC class I immunoreactivity in the cytoplasmic membrane of muscle fibers in IBM and in association with protein aggregates in IBM, and to a lesser degree, in MM. The present findings provide a link between abnormal protein accumulation and altered proteasomal expression in IBM and MM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198127     DOI: 10.1093/jnen/63.5.484

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  24 in total

Review 1.  Myofibrillar myopathies: new developments.

Authors:  Montse Olivé; Rudolf A Kley; Lev G Goldfarb
Journal:  Curr Opin Neurol       Date:  2013-10       Impact factor: 5.710

2.  Sporadic inclusion body myositis: new insights and potential therapy.

Authors:  Pedro M Machado; Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Opin Neurol       Date:  2014-10       Impact factor: 5.710

3.  Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers.

Authors:  Pietro Fratta; W King Engel; Janis McFerrin; Kelvin J A Davies; Sharon W Lin; Valerie Askanas
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

Review 4.  Advances in the immunobiology and treatment of inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

Review 5.  Emerging roles of immunoproteasomes beyond MHC class I antigen processing.

Authors:  Frédéric Ebstein; Peter-Michael Kloetzel; Elke Krüger; Ulrike Seifert
Journal:  Cell Mol Life Sci       Date:  2012-03-02       Impact factor: 9.261

6.  The case for therapeutic proteostasis modulators.

Authors:  Neeraj Vij
Journal:  Expert Opin Ther Targets       Date:  2011-01-21       Impact factor: 6.902

7.  Target genes of neuron-restrictive silencer factor are abnormally up-regulated in human myotilinopathy.

Authors:  Marta Barrachina; Jesús Moreno; Salvador Juvés; Dolores Moreno; Montse Olivé; Isidre Ferrer
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

8.  Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model.

Authors:  Masashi Kitazawa; Vitaly Vasilevko; David H Cribbs; Frank M LaFerla
Journal:  J Neurosci       Date:  2009-05-13       Impact factor: 6.167

9.  Proteasome function is required to maintain muscle cellular architecture.

Authors:  Kevin F Haas; Elvin Woodruff; Kendal Broadie
Journal:  Biol Cell       Date:  2007-11       Impact factor: 4.458

10.  Vacuolar myopathy in a dog resembling human sporadic inclusion body myositis.

Authors:  Jason King; Richard A LeCouteur; Monica Aleman; D Colette Williams; Peter F Moore; Ling T Guo; Andrew P Mizisin; G Diane Shelton
Journal:  Acta Neuropathol       Date:  2009-08-29       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.